How a protein affects immune signaling in melanoma through genome organization
Regulation of interferon signaling in melanoma by the cohesin complex protein STAG2 via 3D genome organization
This study is looking at how a protein called STAG2 affects melanoma, focusing on how its loss changes the way cancer cells organize their DNA and how this might influence the immune system's response to the cancer.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Cedars-Sinai Medical Center NIH-funded |
| Lab location | 1 site (Los Angeles, United States) |
| Project ID | NIH-10914296 on NIH RePORTER |
What this research studies
This research investigates the role of the STAG2 protein in melanoma, particularly how its inactivation affects the organization of the genome within cancer cells. By using advanced techniques like RNA sequencing and chromatin interaction analysis, the study aims to understand how changes in genome structure can influence immune signaling pathways, specifically the type I interferon response. The researchers will explore the molecular mechanisms that lead to increased expression of immune-related proteins, which could impact how melanoma cells interact with the immune system.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with melanoma, particularly those with mutations in the STAG2 gene.
Not a fit: Patients with melanoma who do not have STAG2 mutations or those with other types of cancer may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new therapeutic strategies that enhance immune responses against melanoma.
How similar studies have performed: Previous research has shown that understanding the role of genomic organization in cancer can lead to significant advancements in treatment, suggesting this approach has potential for success.
Where this research is happening
Los Angeles, United States
- Cedars-Sinai Medical Center — Los Angeles, United States (Active)
Researchers
- Principal investigator: Zheng, Bin — Cedars-Sinai Medical Center
- Study coordinator: Zheng, Bin
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.